The immunoreceptor tyrosine-based activation motifs (ITAMs) in the CD3 chains associated with the T cell receptor (TCR) are crucial for TCR signaling. To probe the role of the CD3γ–ITAM in T cell development, we created knock-in mice in which the CD3γ chain of the TCR complex is replaced by a mutant signaling-deficient CD3γ chain, lacking the CD3γ–ITAM. This mutation results in considerable impairment in positive selection in the polyclonal TCR repertoire. When CD3γ–ΔITAM mice are crossed to mice expressing transgenic F5 TCRs, their thymocytes are completely unable to perform positive selection in vivo in response to intrathymic ligands. Also, the in vitro positive selection response of double-positive (DP) thymocytes with F5–CD3γ–ΔITAM mutant receptors to their agonist ligand and many of its variants is severely impaired or abrogated. Yet, the binding and dissociation constants of agonist ligands for the F5 receptor are not affected by the CD3γ–ΔITAM mutation. Furthermore, DP thymocytes with mutant receptors can respond to agonist ligand with normal antigen sensitivity and to normal levels, as shown by their ability to induce CD69 up-regulation, TCR down-regulation, negative selection, and ZAP70 and c-Jun NH2-terminal kinase activation. In sharp contrast, induction of extracellular signal-regulated kinase (ERK) activation and linker for activation of T cells (LAT) phosphorylation are severely impaired in these cells. Together, these findings underscore that intrinsic properties of the TCR–CD3 complex regulate selection at the DP checkpoint. More importantly, this analysis provides the first direct genetic evidence for a role of the CD3γ–ITAM in TCR-driven thymocyte selection.
Skip Nav Destination
Article navigation
1 July 2002
Article|
June 24 2002
Contributions of the T Cell Receptor–associated CD3γ–ITAM to Thymocyte Selection
Mariëlle C. Haks,
Mariëlle C. Haks
1Division of Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands
Search for other works by this author on:
Elsa Pépin,
Elsa Pépin
1Division of Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands
Search for other works by this author on:
Jeroen H.N. van den Brakel,
Jeroen H.N. van den Brakel
1Division of Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands
Search for other works by this author on:
Sigrid A.A. Smeele,
Sigrid A.A. Smeele
1Division of Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands
Search for other works by this author on:
Stanley M. Belkowski,
Stanley M. Belkowski
3Division of Basic Sciences, Immunobiology Working Group, Fox Chase Cancer Center, Philadelphia, PA 19111
Search for other works by this author on:
Helmut W.H.G. Kessels,
Helmut W.H.G. Kessels
1Division of Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands
Search for other works by this author on:
Paul Krimpenfort,
Paul Krimpenfort
2Division of Molecular Genetics, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands
Search for other works by this author on:
Ada M. Kruisbeek
Ada M. Kruisbeek
1Division of Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands
Search for other works by this author on:
Mariëlle C. Haks
1Division of Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands
Elsa Pépin
1Division of Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands
Jeroen H.N. van den Brakel
1Division of Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands
Sigrid A.A. Smeele
1Division of Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands
Stanley M. Belkowski
3Division of Basic Sciences, Immunobiology Working Group, Fox Chase Cancer Center, Philadelphia, PA 19111
Helmut W.H.G. Kessels
1Division of Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands
Paul Krimpenfort
2Division of Molecular Genetics, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands
Ada M. Kruisbeek
1Division of Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands
Address correspondence to Ada M. Kruisbeek, Division of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, Netherlands. Phone: 31-20-5122056; Fax: 31-20-5122057; E-mail: [email protected]
*
Abbreviations used in this paper: DP, double positive; ERK, extracellular signal-regulated kinase; FTOC, fetal thymic organ culture; ITAM, immunoreceptor tyrosine-based activation motif; JNK, c-Jun NH2-terminal kinase; LAT, linker for activation of T cells; RAG, recombination activating gene; SP, single positive; WT, wild-type.
Received:
February 19 2002
Revision Received:
April 16 2002
Accepted:
May 01 2002
Online ISSN: 1540-9538
Print ISSN: 0022-1007
The Rockefeller University Press
2002
J Exp Med (2002) 196 (1): 1–13.
Article history
Received:
February 19 2002
Revision Received:
April 16 2002
Accepted:
May 01 2002
Citation
Mariëlle C. Haks, Elsa Pépin, Jeroen H.N. van den Brakel, Sigrid A.A. Smeele, Stanley M. Belkowski, Helmut W.H.G. Kessels, Paul Krimpenfort, Ada M. Kruisbeek; Contributions of the T Cell Receptor–associated CD3γ–ITAM to Thymocyte Selection . J Exp Med 1 July 2002; 196 (1): 1–13. doi: https://doi.org/10.1084/jem.20020268
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionEmail alerts
Advertisement